Ex-Recursion director plans sale of 100K RXRX shares
RECURSION PHARMACEUTICALS, INC.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
RECURSION PHARMACEUTICALS, INC. (RXRX) has a planned secondary sale of Class A common stock by former director Christopher C. Gibson under Rule 144. The notice covers up to 100,000 Class A shares, with an indicated aggregate market value of 327,500.00, to be sold through Fidelity Brokerage Services LLC on NASDAQ.
The disclosure also lists multiple prior Class A share sales in the past three months by Gibson, Lahwran-3 LLC, and the Gibson Family Trust, with Gibson identified as an authorized individual or trustee for those accounts.
Key Figures
Key Terms
Rule 144 regulatory
attorney-in-fact regulatory
Form 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the Form 144 filing mean for RECURSION PHARMACEUTICALS, INC. (RXRX)?
What prior RXRX stock sales by Christopher C. Gibson are disclosed in the past 3 months?
AI-generated analysis. How Rhea-AI works. Not financial advice.